Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes

Core Insights - Sanofi's Teizeild (teplizumab) has received approval from the European Commission to delay the onset of stage 3 type 1 diabetes (T1D) in patients aged eight years and older with stage 2 disease, following a positive opinion from the European Medicines Agency [1][2] Group 1: Drug Approval and Market Impact - Teizeild is the first disease-modifying drug for T1D authorized in the European Union and is already approved in the United States and other countries for similar indications [2] - The approval is based on the TN-10 phase II study, which demonstrated significant delays in progression from stage 2 to stage 3 T1D, with a median time of 48.4 months for the Teizeild group compared to 24.4 months for the placebo group [5][6] - The study showed that 57% of patients treated with Teizeild remained in stage 2, while only 28% in the placebo group did, with fewer adverse events reported [6] Group 2: Financial and Strategic Context - Teizeild was added to Sanofi's portfolio in 2023 after the company acquired Provention Bio for $2.9 billion, which originally developed the drug [7] - In the first nine months of 2025, Tzield recorded global product sales of €47 million, reflecting a 33.3% increase at constant exchange rates, with €44 million from the United States [8] Group 3: Stock Performance and Comparisons - Over the past year, Sanofi's shares have declined by 1.7%, contrasting with a 21.9% rise in the industry [4] - Sanofi currently holds a Zacks Rank of 3 (Hold), while competitors like Amicus Therapeutics and Indivior have stronger rankings, with Indivior's stock increasing by 208.3% over the past year [9][10]